Search Results - "Hitomi Sezaki"

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus by Akuta, Norio, Kawamura, Yusuke, Watanabe, Chizuru, Nishimura, Akihiro, Okubo, Minoru, Mori, Yasumichi, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Aim The aim of this study was to investigate the therapeutic potential of sodium glucose cotransporter 2 inhibitor (SGLT2I) as an effective therapeutic option…”
Get full text

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology by Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Objective The aim of this study was to determine the long-term effects of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver…”
Get full text

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma by Ikeda, Kenji, Kawamura, Yusuke, Kobayashi, Masahiro, Kominami, Yoko, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Kumada, Hiromitsu

“…Background Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular…”
Get full text

The useful predictors of zinc deficiency for the management of chronic liver disease by Iritani, Soichi, Kawamura, Yusuke, Muraishi, Nozomu, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Kobayashi, Masahiro, Saitoh, Satoshi, Suzuki, Fumitaka, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu

“…Background Zinc deficiency is likely to occur in chronic liver disease. The aim of this study was to determine the prevalence of zinc deficiency in different…”
Get full text

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients by Ono, Atsushi, Suzuki, Fumitaka, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitou, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Watahiki, Sachiyo, Mineta, Rie, Kumada, Hiromitsu

“…Background & Aims We determined the antiviral potency and viral resistance rate after 4 years of continuous entecavir treatment in patients with chronic…”
Get full text

Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs by Yamashige, Daiki, Hosaka, Tetsuya, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Kumada, Hiromitsu

“…Background Few studies have demonstrated the potency of tenofovir alafenamide (TAF) in patients with poor response to other nucleos(t)ide analogs (NAs)…”
Get full text

Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b by Ogasawara, Nobuhiko, Kobayashi, Masahiro, Akuta, Norio, Kominami, Yoko, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Suzuki, Fumitaka, Saitoh, Satoshi, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Kumada, Hiromitsu

“…Little information is available on the impact of direct‐acting antiviral (DAA) therapy on changes in liver fibrosis and steatosis. Liver stiffness (LS) and…”
Get full text

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study by Hosaka, Tetsuya, Suzuki, Fumitaka, Kobayashi, Masahiro, Seko, Yuya, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Kumada, Hiromitsu

“…Background Clearance of hepatitis B surface antigen (HBsAg) is considered the ultimate goal in chronic hepatitis B treatment. One treatment option is long-term…”
Get full text

Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors by Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Nakamichi, Kenichi, Saegusa, Eiji, Ogura, Hidetoshi, Kato, Masaki, Doi, Etsuko, Inoue, Naoko, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu, Suzuki, Fumitaka

“…Aims Both diet and exercise counseling are recommended for patients with fatty liver, including nonalcoholic fatty liver disease (NAFLD), to achieve weight…”
Get full text

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib by Kasuya, Kayoko, Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Kajiwara, Akira, Iritani, Soichi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Eguchi, Yuichiro, Hashimoto, Masaji, Kumada, Hiromitsu

“…Objective A survival benefit was demonstrated for ramucirumab (RAM) in patients with unresectable hepatocellular carcinoma (uHCC) and α-fetoprotein (AFP)…”
Get full text

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C by Ogasawara, Nobuhiko, Saitoh, Satoshi, Akuta, Norio, Sezaki, Hitomi, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Aim The risk of development of hepatocellular carcinoma (HCC) persisted in patients with advanced fibrosis, even after achieving sustained virologic response…”
Get full text

Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance by Suzuki, Fumitaka, Hosaka, Tetsuya, Imaizumi, Masayasu, Kobayashi, Mariko, Ohue, Chiharu, Suzuki, Yoshiyuki, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Kobayashi, Masahiro, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Aims Hepatitis B surface antigen (HBsAg) seroclearance indicates a “functional cure” in chronic hepatitis B (CHB) virus infection. However, several cases of…”
Get full text

Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan by Akuta, Norio, Sezaki, Hitomi, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Predictors of treatment efficacy with ledipasvir plus sofosbuvir as direct‐acting antiviral (DAA) regimen for HCV infection are still unclear. Retreatment…”
Get full text

Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy by Ogasawara, Nobuhiko, Saitoh, Satoshi, Akuta, Norio, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Aim The long‐term effects of sustained virologic response (SVR) to antiviral therapy on the risk of liver complications, such as exacerbation of esophageal…”
Get full text

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections by Sezaki, Hitomi, Suzuki, Fumitaka, Hosaka, Tetsuya, Fujiyama, Shunichirou, Kawamura, Yusuke, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Kumada, Hiromitsu

“…Background Glecaprevir and pibrentasvir (GLE/PIB) are potent antiviral agents for hepatitis C virus (HCV) pan-genotypic infections; however, their clinical…”
Get full text

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens by Akuta, Norio, Sezaki, Hitomi, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…There is little information on retreatment efficacy and predictors of the combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir) for patients who…”
Get full text

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD by Akuta, Norio, Kawamura, Yusuke, Arase, Yasuji, Saitoh, Satoshi, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Suzuki, Yoshiyuki, Suzuki, Fumitaka, Ikeda, Kenji, Kumada, Hiromitsu

“…Abstract Background Reliable noninvasive predictors of the top three causes of death [cardiovascular diseases (CVDs), malignancies, and liver-related events in…”
Get full text

Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment by Muraishi, Nozomu, Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Okubo, Satoshi, Iritani, Soichi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, Yasuda, Ichiro, Kumada, Hiromitsu

“…Objective The relationship between the prognosis and magnitude of a decrease in tumor blood flow according to estimated tumor differentiation remains unclear…”
Get full text

Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease by Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Nakamichi, Kenichi, Saegusa, Eiji, Ogura, Hidetoshi, Kato, Masaki, Doi, Etsuko, Inoue, Naoko, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu, Suzuki, Fumitaka

“…Aims The effects of genetic polymorphism on a personalized diet and exercise program for steatotic liver disease (SLD) are still unclear. Methods Participants…”
Get full text

Long-term Favorable Efficacy of Regular and Repeated Hospitalizations with a Personalized Diet and Exercise Treatment for Steatotic Liver Disease by Akuta, Norio, Kawamura, Yusuke, Sezaki, Hitomi, Nakamichi, Kenichi, Saegusa, Eiji, Ogura, Hidetoshi, Kato, Masaki, Doi, Etsuko, Inoue, Naoko, Hosaka, Tetsuya, Saitoh, Satoshi, Kobayashi, Mariko, Fujiyama, Shunichiro, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu, Suzuki, Fumitaka

“…Objective The long-term impact of personalized diet and exercise programs for steatotic liver disease (SLD) remains unclear. Materials The subjects of this…”
Get full text